Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,013 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Viral Infections Clear all

Conditions: Influenza
Interventions: Data collection; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Trivalent influenza vaccine GSK 138842A, Fluarix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Influenza Virus
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: 2009 H1N1 Influenza
Interventions: Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 4 Years to 9 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy
Interventions: Sucrose, Galactooligosaccharide; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 60 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pandemic H5N1 Influenza
Interventions: Adjuvanted H5N1 pandemic influenza vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 662 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Miami, Florida • Newton, Kansas • Wichita, Kansas + 6 more

Conditions: H1N1 Influenza Treatment During Pregnancy
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more

Conditions: Pandemic Influenza
Interventions: H5N1 VLP Vaccine, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza
Interventions: CR8020, CR6261, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more

Conditions: Influenza, Human
Interventions: Influenza Vaccine; Biological
Lead sponsor: PharmaJet, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 985 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Influenza
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 3,022 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Influenza, Vaccination, Risk Reduction, Health Behavior, Health Promotion
Interventions: Risk reduction; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 51,218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Influenza
Interventions: Blood Draw; Procedure
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections, Orthomyxoviridae Infections, RNA Virus Infections, Virus Diseases, Respiratory Tract Diseases
Interventions: aH5N6c on Day 1, aH5N6c on Day 22, Placebo on Day 22; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Huntsville, Alabama • Tempe, Arizona • San Diego, California + 14 more

Conditions: Influenza
Interventions: oseltamivir [Tamiflu]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: West Palm Beach, Florida • Pittsburgh, Pennsylvania • Jackson, Tennessee + 1 more

Conditions: Viral Vaccines
Interventions: Influenza vaccination, SARS-CoV-2 vaccine, Zoster Vaccine Recombinant; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: favipiravir, Placebo; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 60
States / cities: Birmingham, Alabama • Hunstville, Alabama • Hot Springs, Arkansas + 48 more

Conditions: Influenza Prevention, Pandemic Influenza Prevention
Interventions: VRC-FLUMOS0122-00-VP, ALFQ; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza, Human
Interventions: F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z, F2B22C/DL001Z, F2B22D/DL001Z, F2B22E/DL001Z, F2F22A/DL001Z, F2F22B/DL001Z, F2F22C/DL001Z, F2F22D/DL001Z, F2F22E/DL001Z, Control 1, F2F23D/DL001Z-NH, F2F23A/DL001Z-NH, F2F23B/DL001Z-NH, Control 2, F2F23C/DL001Z-NH, Control 3, F2F22F/DL001Z; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more

Conditions: Healthy, Influenza
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: San Diego, California • Daytona Beach, Florida • Portland, Oregon + 1 more

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: Not listed
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza Infection
Interventions: VAX102 [Flagellin.HuM2e], Placebo; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Lenexa, Kansas • Galveston, Texas

Conditions: Influenza a, Influenza B, RSV, COVID 19
Interventions: LIAISON NES FLU A/B, RSV & COVID-19; Diagnostic Test
Lead sponsor: DiaSorin Molecular LLC; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Henderson, Nevada • Pittsburgh, Pennsylvania • McAllen, Texas

Search by objective public record fields.

Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States

Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

A Study of the Pharmacology of Tamiflu in Pregnancy

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

Inactivated Influenza Via Jet Injection

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

Rule-Based High-Risk Flu

Immunogenicity of Influenza Vaccine in Long Term Care

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.

Vaccine Responses in Cancer

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Influenza Vaccine in Lung Transplant Patients - Antibody

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients